article thumbnail

Site-Specific Molecular Glues for the 14-3-3/Tau pS214 ProteinProtein Interaction via Reversible Covalent Imine Tethering

Covalent Modifiers

DOI Ansgar Oberheide, Maxime van den Oetelaar, Jakob Scheele, Jan Borggrfe, Semmy Engelen, Michael Sattler, Christian Ottmann, Peter Cossar and Luc Brunsveld RSC Med Chem 2025 [link] Protein-protein interactions (PPIs) are key regulators of various cellular processes.

article thumbnail

Bristol Myers faces FDA delay on cancer cell therapy decision

BioPharma Drive: Drug Pricing

The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

Therapies 274
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Finalizes Limit on How Much Arsenic Can Be in Apple Juice

Drugs.com

WEDNESDAY, June 7, 2023 -- Federal regulators have finalized new guidance on how much inorganic arsenic can be present in apple juice, in an effort to limit the exposure of infants and young children to this environmental contaminant. What is the.

FDA 246
article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

While treating rare diseases presents significant challenges due to small patient populations and limited financial incentives, the Orphan Products Grants Program provides crucial financial support to help bridge the gap between early research and successful treatment development.

article thumbnail

Nuclear Receptors: A new mode of inhibition

Covalent Modifiers

link] The article presents the discussion on interaction of covalent inhibitors GW9662 and T0070907 with the peroxisome proliferator-activated receptor gamma (PPARγ), revealing new insights into how these compounds influence receptor activity. Andrew D Huber, Taosheng Chen eLife 2024, 13 :e101446.

article thumbnail

Hsa?miR?503?5p regulates CTDSPL to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells

Chemical Biology and Drug Design

Hsa-miR-503-5p negatively regulates CTDSPL, suggesting its potential as a target to overcome cisplatin resistance in LUAD. The results showed that hsa-miR-503-5p showed high expression, while its target gene CTDSPL presented decreased expression in LUAD. Hsa-miR-503-5p also had high expression in cisplatin-resistant LUAD cells.

article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

For example, transcriptomic processes are showing the potential to identify and track failures in gene expression and gene regulation of amyloid and tau-related biomarkers, understood as precursors to the onset of Alzheimers disease (AD). For use as endpoints, biomarkers must be correlated to a valid clinical outcome.